IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells

Blood

Volumn 103, Issue 10, 2004, Pages 3837-3844

  Tecchio, Cristina ^b   Huber, Veronica ^b   Scapini, Patrizia ^b   Calzetti, Federica ^b   Margotto, Daniela ^b   Todeschini, Giuseppe ^b   Pilla, Lorenzo ^b   Martinelli, Giovanni ^b   Pizzolo, Giovanni ^b   Rivoltini, Licia ^b   Cassatella, Marco A ^a  

^a Department of Pathology and Diagnostics   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; DEATH RECEPTOR 1; DEATH RECEPTOR 5; FC RECEPTOR; MESSENGER RNA; NEUTRALIZING ANTIBODY; SOLUBLE TUMOR NECROSIS FACTOR APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; MEMBRANE PROTEIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOREGULATION; LEUKEMIA CELL; MELANOMA; MONOCYTE; NEUTROPHIL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SECRETION; BLOOD; CELL CULTURE; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; PATHOLOGY; SOLUBILITY; UPREGULATION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELLS, CULTURED; DRUG EVALUATION; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOCYTES; NEUTROPHILS; SOLUBILITY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 2342623331     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-08-2806     Document Type: Article

References (45)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-662.
2. Pitti RM, Marsters SA, Ruppert S, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687-12690.
3. Mariani SM, Krammer PH. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur J Immunol. 1998;28:1492-1498.
4. Martinez-Lorenzo MJ, Alava MA, Gamen S, et al. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol. 1998;28:2714-2725.
5. Halaas Ø, Vik R, Ashkenazi A, Espevik T. Lipopolysaccaride induces expression of APO2 Ligand/ TRAIL in human monocytes and macrophages. Scand J Immunol. 2000;51:244-250.
6. Monleon I, Martinez-Lorenzo MJ, Monteagudo L, et al. Differential secretion of Fas Ligand or APO2 Ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol. 2001;167:6736-6744.
7. Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
8. LeBlank HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 2003;10:66-75.
9. Wajant H, Pfizenmaler K, Scheurich P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis. 2002;7:449-459.
10. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 1999;5:157-163.
11. Griffith TS, Wiley SR, Kubin MZ, et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med. 1999;8:1343-1353.
12. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med. 1999;190:1155-1164.
13. Yu Y, Shuxun L, Wang W, et al. Involvement of tumor-necrosis factor-α-related apoptosis-inducing ligand in enhanced cytotoxicity of lipopolysaccaride-stimulated dendritic cells to activated T cells. Immunology. 2002;106:308-315.
14. Dorothée G, Vergnon I, Menez J, et al. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-α on APO2L/TRAIL expression and mediated cytotoxicity. J Immunol. 2002;169:809-817.
15. Smyth MJ, Cretney E, Takeda K, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis. J Exp Med. 2001;193:661-670.
16. Vidalain P, Azocar O, Lamouille B, et al. Measles virus induces functional TRAIL production by human dendritic cells. J Virol. 2000;74:556-559.
17. Washburn B, Weigand MA, Grosse-Wilde A, et al. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle Disease Virus. J Immunol. 2003;170:1814-1821.
18. Seki N, Hayakawa Y, Brooks AD, et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 2003;63:207-213.
19. Cretney E, Takeda K, Yagita H, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol. 2002;168:1356-1361.
20. Nieda M, Nicol A, Koezuka Y, et al. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood. 2001;97:2067-2074.
21. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med. 2002;195:161-169.
22. Schmaltz C, Alpdogan O, Kappel BJ, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med. 2002;8:1433-1437.
23. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical application in cancer. Neoplasia. 2001;3:535-546.
24. Cassatella MA. Neutrophil-derived proteins: selling cytokines by the pound. Adv Immunol. 1999;73:369-509.
25. Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functionally BLyS. J Exp Med. 2003;197:297-302.
26. Baccarani M, Rosti G, de Vivo A, et al. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527-1535.
27. Cassatella MA, Bazzoni F, Flynn RM, et al. Molecular basis of interreron-γ and lipopolysaccharide enhancement of phagocyte respiratory burst capability: studies on the gene expression of several NADPH oxidase components. J Biol Chem. 1990;265:20241-20246.
28. Zamai L, Ahmad M, Bennett IM, et al. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med. 1998;188:2375-2360.
29. Gasperini S, Marchi M, Calzetti F, et al. Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol. 1999;162:4928-4937.
30. Stylianou E, Yndestad A, Sikkeland LI, et al. Effects of interferon-α on gene expression of chemokines and members of the tumor necrosis factor superfamily in HIV-infected patients. Clin Exp Immunol. 2002;130:279-285.
31. Renshaw SA, Timmons SJ, Eaton V, et al. Inflammatory neutrophils retain susceptibility to apoptosis mediated via the Fas death receptor. J Leukoc Biol. 2000;67:662-668.
32. Renshaw SA, Parmar JS, Singleton V, et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol. 2003;170:1027-1033.
33. Gordon MY, Marley SB, Lewis JL, et al. Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukaemia but spares normal CFU-GM. J Clin Invest. 1998;102:710-715.
34. Muhlenbeck F, Schneider P, Bodmer J-L, et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem. 2000;275:32208-32213.
35. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155-162.
36. Clarke P, Meintzer SM, Gibson S, et al. Reovirus-induced apoptosis is mediated by TRAIL. J Virol. 2000;74:8135-8139.
37. Wajant H, Moosmayer D, Wuest T, et al. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows a selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene. 2001;20:4101-4106.
38. Aoki K, Kurooka M, Chen J, et al. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat Immunol. 2001;2:333-337.
39. Brassard DL, Grace MJ, Bordens RW. Interferon-α as an immunotherapeutic protein. J Leukoc Biol. 2002;71:565-581.
40. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukaemia. N Engl J Med. 1999;341:164-172.
41. Uno K, Inukai T, Kayagaki N, et al. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukaemia cells. Blood. 2003;101:3658-3667.
42. Wandinger K, Lunemann JD, Wengert O, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet. 2003;361:2036-2043.
43. Plasilova M, Zivny J, Jelinek J, et al. TRAIL (Apo2L) suppresses growth of primary human leukaemia and myelodysplasia progenitors. Leukemia. 2002;16:67-73.
44. Nimmanapalli R, Porosnicu M, Nguyen D, et al. Cotreatment with STI571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukaemia cells. Clin Cancer Res. 2001;7:350-357.
45. Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL - on a path to cancer immunotherapy. Immunity. 2003;18:1-6.